Skip to main content

Imunon, Inc.

For the period ended Dec 31, 2025. Filed Mar 31, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 31, 2026

IMNN$0.88+4.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 16. FORM 10-K SUMMARY

Not applicable.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

IMUNON, INC.
Registrant
March 31, 2026By:/s/ Stacy Lindborg, Ph.D.
Stacy Lindborg, Ph.D.
Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

NamePositionDate
/s/ MICHAEL H. TARDUGNOExecutive Chairman of the BoardMarch 31, 2026
(Michael H. Tardugno)
/s/ STACY R. LINDBORG, Ph.D.President, Chief Executive Officer and DirectorMarch 31, 2026
(Stacy R Lindborg, Ph.D.)(Principal Executive Officer)
/s/ JEFFREY W. CHURCHChief Financial OfficerMarch 31, 2026
(Jeffrey W. Church)(Principal Financial Officer and Principal Accounting Officer)
/s/ FREDERICK J. FRITZDirectorMarch 31, 2026
(Frederick J. Fritz)
/s/ JAMES E. DENTZERDirectorMarch 31, 2026
(James E. Dentzer)
/s/ DONALD BRAUNDirectorMarch 31, 2026
(Donald Braun, Ph.D.)
/s/ CHRISTINE PELLIZZARIDirectorMarch 31, 2026
(Christine A. Pellizzari)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.